Seven manufacturers of Remdesivir have increased production capacity to 1.03 crore vials per month up from 38 lakh vials per month a month ago
The company will be requesting a Compulsory License based on emergency use and in light of the grave and serious public health emergency across India due to the Pandemic
The progress has been encouraging with approvals and launches in the US, EU, Japan, Australia and Emerging Markets. Post Mylan Upjohn (Pfizer) merger, the scope has been extended to China as well.
The Government of India has started importing the vital drug Remdesivir from other countries to ease out the shortage of Remdesivir in the country
This oxygen is being provided free-of-cost to several state governments across the country to bring immediate relief to over 1 lakh patients on a daily basis
Riding COVID-19 wave, Indian vaccine industry set to be Rs. 700 billion strong
The U.S. Development Finance Corporation is funding a substantial expansion of manufacturing capability for BioE, the vaccine manufacturer in India
Apart from the above, it was also decided that Basic Customs Duty on import of COVID-19 vaccines be also exempted with immediate effect for a period of 3 months
In animal health, the products will be mainly targeting mastitis and production disorders, gastrointestinal tract diseases, reproductive disorders, ectoparasites, and skin injuries
Market penetration of Sputnik V will depend on competitive pricing, government orders and the ability to meet soaring demand through timely supply
Subscribe To Our Newsletter & Stay Updated
